- Home
- GHXI vs GALT Comparison
GHXI vs GALT Comparison
Compare GHXI & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$3.18
Company Overview
Basic Information| Metric | GHXI | GALT |
|---|---|---|
| Founded | 2025 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 450.3M | 397.3M |
| IPO Year | 2026 | 2008 |
Fundamental Metrics
Financial Performance| Metric | GHXI | GALT |
|---|---|---|
| Price | $9.90 | $3.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 139.9K | ★ 190.7K |
| Earning Date | N/A | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.90 | $2.03 |
| 52 Week High | $10.11 | $7.13 |
Technical Indicators
Market Signals| Indicator | GHXI | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 38.40 | 32.30 |
| Support Level | N/A | $2.71 |
| Resistance Level | $10.11 | $3.30 |
| Average True Range (ATR) | 0.02 | 0.23 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 0.00 | 1.73 |
Price Performance
Historical Comparison GHXI
GALT
About GHXI Gores Holdings XI Inc. Class A Ordinary Shares
Gores Holdings XI Inc is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.